Pages that link to "Q28212185"
Jump to navigation
Jump to search
The following pages link to Genetic cause of hyperglycaemia and response to treatment in diabetes (Q28212185):
Displaying 50 items.
- Maturity-Onset Diabetes of the Young: What Do Clinicians Need to Know? (Q26771916) (← links)
- Personalized medicine in diabetes: the role of 'omics' and biomarkers (Q26775259) (← links)
- Insights into the genetic basis of type 2 diabetes (Q26859885) (← links)
- Pathogenesis of the metabolic syndrome: insights from monogenic disorders (Q27024024) (← links)
- (Q28179314) (redirect page) (← links)
- Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery (Q28274686) (← links)
- Gene-Lifestyle Interactions in Complex Diseases: Design and Description of the GLACIER and VIKING Studies (Q28397345) (← links)
- Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells (Q28473974) (← links)
- Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers (Q28481662) (← links)
- Personalized medicine in Type 2 Diabetes (Q28542708) (← links)
- Development of an economic evaluation of diagnostic strategies: the case of monogenic diabetes (Q28689671) (← links)
- Human genetics as a model for target validation: finding new therapies for diabetes (Q30234640) (← links)
- Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth (Q30548217) (← links)
- Precision diabetes: learning from monogenic diabetes (Q33453490) (← links)
- Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes (Q33602114) (← links)
- Many faces of monogenic diabetes (Q33622236) (← links)
- Approach to the patient with atypical diabetes (Q33728464) (← links)
- Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms (Q33813015) (← links)
- Genetic epidemiology of diabetes (Q33831947) (← links)
- The Genetic Architecture of Diabetes in Pregnancy: Implications for Clinical Practice. (Q33898977) (← links)
- Genetic Counseling for Diabetes Mellitus (Q33899140) (← links)
- Fasting serum C-peptide is useful for initial classification of diabetes mellitus in children and adolescents (Q33964774) (← links)
- Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations (Q34084456) (← links)
- Clinical translation of genetic predictors for type 2 diabetes (Q34124681) (← links)
- Pharmacogenetics of Anti-Diabetes Drugs (Q34181995) (← links)
- A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. (Q34205887) (← links)
- Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and beta cell failure. (Q34403650) (← links)
- Pharmacogenetics in clinical practice: considerations for testing (Q34499056) (← links)
- Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes (Q34507037) (← links)
- Diabetic ketoacidosis in the setting of HNF1A-maturity onset diabetes of the young (Q35467563) (← links)
- Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population (Q35588251) (← links)
- Predicting disease using genomics (Q35784521) (← links)
- The genetics and pathophysiology of diabetes mellitus type II. (Q35800511) (← links)
- Genetics of Type 2 Diabetes and Clinical Utility. (Q35808509) (← links)
- Pharmacogenetics in type 2 diabetes: potential implications for clinical practice (Q35840645) (← links)
- What Is the Best NGS Enrichment Method for the Molecular Diagnosis of Monogenic Diabetes and Obesity? (Q35850123) (← links)
- Transcriptional networks controlling pancreatic development and beta cell function. (Q35857682) (← links)
- The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. (Q35894994) (← links)
- Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young (Q35976364) (← links)
- Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c? (Q35981408) (← links)
- Clinical features and treatment of maturity onset diabetes of the young (MODY). (Q35997281) (← links)
- Genetics of Type 2 diabetes. (Q36103109) (← links)
- Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetes (Q36157483) (← links)
- Genetic and clinical characteristics of maturity-onset diabetes of the young (Q36162489) (← links)
- Monogenic models: what have the single gene disorders taught us? (Q36369882) (← links)
- What will diabetes genomes tell us? (Q36374101) (← links)
- Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young (Q36501677) (← links)
- Defining the genetic aetiology of monogenic diabetes can improve treatment (Q36573898) (← links)
- Phenotypic heterogeneity in monogenic diabetes: the clinical and diagnostic utility of a gene panel-based next-generation sequencing approach (Q36588444) (← links)
- Monogenic diabetes in children and young adults: Challenges for researcher, clinician and patient (Q36691238) (← links)